drugset
drugset / Trial / NCT00756743

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

NCT00756743 ↗

Phase 1 Completed 40 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedCrossoverTriple-blind

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.

Timeline

Start
2008-09
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04802540 Unknown 5 mg Oral
Subject PF-04802540 Unknown 10 mg Oral
Subject PF-04802540 Unknown 15 mg Oral

Indications

No indication recorded.